Sanofi boosts Lantus insulin production in Ireland
PARIS Feb 13 (Reuters) - French drugmaker Sanofi said on Wednesday it would invest 44 million euros ($59 million) on its site in Waterford, Ireland, to boost production of its top-selling insulin, Lantus.
The company, which has been reshuffling research and production sites in the United States and Europe after the patent loss of several key medicines, aims to start making Lantus at the site in 2016, Sanofi said in a statement.
Lantus is expected to continue its double-digit sales growth after the U.S. Food and Drug Administration this week refused to approve Novo Nordisk's rival insulin Tresiba until the Danish company conducts extra tests for potential heart risks.
- Pennsylvania newlyweds "just wanted to murder someone together:" police
- WTO overcomes last minute hitch to reach its first global trade deal
- U.S. freeze shows no sign of weekend melt after deadly storm
- Colorado baker discriminated by denying gay couple wedding cake: judge
- North Korea frees U.S. Korean War veteran after seven weeks |